Search clinical trials for: 200 mg AVL-292

Total 12217 results

University of Michigan Rogel Cancer Center

Withdrawn

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Atabay Kimya Sanayi Ticaret A.S.
Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. Sti

Unknown

The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions (Umifenovir)

Bioequivalence

Turkey
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Levothyroxine Sodium Tablets 200 mg to Synthroid Tablets 200 mg

Healthy

United States
Evofem Inc.
Neothetics, Inc

Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Central Abdominal Bulging
Centre hospitalier de l'Université de Montréal...

Completed

A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users

Cannabis

Canada
Galapagos NV

Completed

Oral Bioavailability of Two Solid Formulations of GLPG0634

Healthy

Belgium
Bayer
Amgen

Completed

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Carcinoma

United States
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes Type 2

Japan
Novartis Pharmaceuticals

Recruiting

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Non-Small Cell Lung Carcinoma

India
Gannex Pharma Co., Ltd.
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
University of Florida

Recruiting

Can Cranberry Juice Enhance the Cognition Accuracy and Alleviate Negative Mental Consequences During Multitasking?

Motor Activity | Cognitive Symptom | Stress Response | Mental Stress | Physiological Stress | Multitasking Behavior

United States
Atabay Kimya Sanayi Ticaret A.S.
Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. Sti

Completed

Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions (Favipiravir)

Bioequivalence

Turkey
Novelfarma Ilaç San. ve Tic. Ltd. Sti.
Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. Sti

Completed

Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions (Favipiravir)

Bioequivalence

Turkey
World Medicine ILAC SAN. ve TIC. A.S.
Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. Sti

Completed

Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions (Favipiravir)

Bioequivalence

Turkey
Tibotec Pharmaceuticals, Ireland

Withdrawn

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

HIV Infections

Netherlands
MedImmune LLC

Completed

A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

Asthma

United States
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Immune-Onc Therapeutics
California Institute for Regenerative Medicine (CIRM)

Recruiting

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

CMML | AML With Monocytic Differentiation

United States
JMackem Co., Ltd
Seoul National University Hospital

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects

Diabetic Neuropathies | Neuropathic Pain | Post Herpetic Neuralgia

Korea, Republic of
CymaBay Therapeutics, Inc.

Completed

Study to Evaluate the Effects of MBX-8025 in Patients With HoFH

Homozygous Familial Hypercholesterolemia

Canada, France, Netherlands, Norway
Devalingam Mahalingam
GenSpera, Inc.

No longer available

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
GenSpera, Inc.

Withdrawn

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer.

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
University Hospital, Toulouse

Terminated

Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart Failure (B2AN-SNS)

Heart Failure

France
Virginia Commonwealth University
GlaxoSmithKline; Puma Biotechnology, Inc.

Recruiting

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE)

Ovarian Cancer | Advanced Solid Tumor

United States
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Pfizer

Active, not recruiting

A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

Atopic Dermatitis

India
Stephen Bagley, MD, MSCE
University of Pennsylvania; Abramson Cancer Center at Penn Medicine

Active, not recruiting

Abemaciclib in Patients With Oligodendroglioma

Oligodendroglioma, Adult

United States
LG Chem

Completed

Renal PK Study of LC350189

Hyperuricemia | Gout

United States
BioCryst Pharmaceuticals

Completed

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Cutaneous T-cell Lymphoma (CTCL),

United States, Australia, Germany, Italy, Spain, France, Austria, Finland, Switzerland, United Kingdom
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation

Recruiting

A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa (CoTeT)

COVID-19

South Africa
Jair Bar, M.D., Ph.D.
Merck Sharp & Dohme LLC

Completed

Anti PD-1 Neo-adjuvant Treatment for NSCLC (MK3475-223)

Non Small Cell Lung Carcinoma | Stage II | Stage I

Israel
GenSpera, Inc.
Saint John's Cancer Institute

Withdrawn

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

Glioblastoma

United States
REGENXBIO Inc.

Recruiting

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
Alpine Immune Sciences, Inc.

Terminated

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)

Lymphoma | Advanced Solid Tumor

United States, Australia
GenSpera, Inc.

Completed

Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme

United States
GenSpera, Inc.

Completed

Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Neothetics, Inc

Unknown

An Open-Label Study to Evaluate Retreatment With LIPO-202

Central Abdominal Bulging

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Rheumatoid Arthritis

United States, Poland, Germany, Mexico, Brazil, Czech Republic, Argentina
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
Kowa Research Institute, Inc.

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

Hyperlipidemia

United States
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

Healthy

United States
Spinifex Pharmaceuticals Pty Ltd
Syneos Health

Withdrawn

Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN

Neuralgia, Postherpetic
Seoul Medical Center

Completed

ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty

Spinal Anesthesia | Total Knee Replacement Arthroplasty

Korea, Republic of
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
PHARMENTERPRISES LLC

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

Influenza | Acute Respiratory Infection

Russian Federation
Pharma Plant
Novagenix Bioanalytical Drug R&D Center

Unknown

Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions

Bioequivalence

Turkey
Inversago Pharma Inc.

Active, not recruiting

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Obesity | Metabolic Syndrome

Canada
Inversago Pharma Inc.

Completed

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Metabolic Syndrome

Canada

Search clinical trials for: 200 mg AVL-292

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations